Abbott Laboratories (ABT)

Currency in USD
131.64
+0.95(+0.73%)
Real-time Data·
ABT Scorecard
Full Analysis
Has raised its dividend for 11 consecutive years
ABT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
129.81131.72
52 wk Range
107.11141.23
Key Statistics
Prev. Close
130.69
Open
130.07
Day's Range
129.81-131.72
52 wk Range
107.11-141.23
Volume
1.59M
Average Volume (3m)
6.63M
1-Year Change
20.31%
Book Value / Share
29.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
142.48
Upside
+8.24%
Members' Sentiments
Bearish
Bullish
ProTips
20 analysts have revised their earnings downwards for the upcoming period

Abbott Laboratories News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories SWOT Analysis


PFA System Triumph
Abbott's early EU approval for the PFA System positions it as a frontrunner in electrophysiology, potentially reshaping market dynamics and boosting growth prospects
Financial Resilience
Explore Abbott's robust financial health, with 10.1% organic revenue growth and a projected 7.5-8.5% increase for 2025, showcasing its market strength
Analyst Perspectives
Average price target of $139, ranging from $130 to $158, reflecting varied views on Abbott's growth potential and market position
Strategic Challenges
Delve into Abbott's ongoing litigation risks and competitive pressures in diabetes management, balancing against its diversified portfolio and innovation pipeline
Read full SWOT analysis

Abbott Laboratories Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $1.26 beat $1.25 forecast; revenue of $11.42B exceeded $11.07B estimate, up 6.9% YoY
  • Stock fell 7.21% pre-market despite earnings beat, closing at $124.54; market cap remains strong at $212.26B
  • Core business growth offset declining COVID test sales; Libre CGM and new product launches drove performance
  • Company forecasts high single-digit sales growth for 2025, projects similar growth with double-digit EPS rise for 2026
  • CEO highlights resilient, diversified model; focus on innovation and biosimilars expansion to drive future growth
Last Updated: 17/07/2025, 15:22
Read Full Transcript

Compare ABT to Peers and Sector

Metrics to compare
ABT
Peers
Sector
Relationship
P/E Ratio
16.3x−41.2x−0.5x
PEG Ratio
0.110.080.00
Price/Book
4.5x8.4x2.6x
Price / LTM Sales
5.3x3.6x3.3x
Upside (Analyst Target)
9.5%46.3%42.8%
Fair Value Upside
Unlock−26.2%6.5%Unlock

Analyst Ratings

20 Buy
7 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 142.48
(+8.24% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.01%
Dividend Yield
1.81%
Industry Median 1.32%
Annualised payout
2.36
Paid quarterly
5-Years Growth
+10.63%
Growth Streak

Earnings

Latest Release
Jul 17, 2025
EPS / Forecast
1.26 / 1.25
Revenue / Forecast
11.42B / 11.07B
EPS Revisions
Last 90 days

ABT Income Statement

People Also Watch

195.79
ABBV
-1.39%
156.97
RTX
+0.41%
171.11
JNJ
+0.22%
70.99
NEE
-0.27%
63.23
MO
+1.14%

FAQ

What Stock Exchange Does Abbott Labs Trade On?

Abbott Labs is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Abbott Labs?

The stock symbol for Abbott Labs is "ABT."

What Is the Abbott Labs Market Cap?

As of today, Abbott Labs market cap is 229.03B.

What Is Abbott Labs's Earnings Per Share (TTM)?

The Abbott Labs EPS (TTM) is 8.01.

When Is the Next Abbott Labs Earnings Date?

Abbott Labs will release its next earnings report on 14 Oct 2025.

From a Technical Analysis Perspective, Is ABT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abbott Labs Stock Split?

Abbott Labs has split 7 times.

How Many Employees Does Abbott Labs Have?

Abbott Labs has 114000 employees.

What is the current trading status of Abbott Labs (ABT)?

As of 06 Aug 2025, Abbott Labs (ABT) is trading at a price of 131.64, with a previous close of 130.69. The stock has fluctuated within a day range of 129.81 to 131.72, while its 52-week range spans from 107.11 to 141.23.

What Is Abbott Labs (ABT) Price Target According to Analysts?

The average 12-month price target for Abbott Labs is USD142.4848, with a high estimate of USD159 and a low estimate of USD122. 20 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +8.24% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.